{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:21:56Z","timestamp":1790767316984,"version":"4.1.0"},"reference-count":14,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2023,10,10]]},"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1183\/13993003.01726-2023","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T10:35:54Z","timestamp":1698921354000},"page":"2301726","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Viewpoint: activin signalling inhibitors for the treatment of pulmonary arterial hypertension"],"prefix":"10.1183","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2892","authenticated-orcid":false,"given":"Marc","family":"Humbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"2024102012381394000_62.5.2301726.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022"},{"key":"2024102012381394000_62.5.2301726.2","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"2024102012381394000_62.5.2301726.3","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-1460"},{"key":"2024102012381394000_62.5.2301726.4","doi-asserted-by":"crossref","first-page":"2102311","DOI":"10.1183\/13993003.02311-2021","article-title":"COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension","volume":"60","author":"Hoeper","year":"2021","journal-title":"Eur Respir J"},{"key":"2024102012381394000_62.5.2301726.5","doi-asserted-by":"crossref","first-page":"2102419","DOI":"10.1183\/13993003.02419-2021","article-title":"External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry","volume":"59","author":"Boucly","year":"2021","journal-title":"Eur Respir J"},{"key":"2024102012381394000_62.5.2301726.6","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-2600(23)00264-3","article-title":"Treatment of pulmonary arterial hypertension: recent progress and a look to the future","volume":"11","author":"Humbert","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024102012381394000_62.5.2301726.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01887-2018"},{"key":"2024102012381394000_62.5.2301726.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02341-2020"},{"key":"2024102012381394000_62.5.2301726.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024277"},{"key":"2024102012381394000_62.5.2301726.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01347-2022"},{"key":"2024102012381394000_62.5.2301726.11","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"2024102012381394000_62.5.2301726.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01107-2023"},{"key":"2024102012381394000_62.5.2301726.13","unstructured":"Merck. Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH). Date last updated: 28 September 2023. Date last accessed: 1 October 2023. www.merck.com\/news\/merck-receives-priority-review-from-fda-for-new-biologics-license-application-for-sotatercept-an-activin-signaling-inhibitor-to-treat-adults-with-pulmonary-arterial-hypertension-pah\/"},{"key":"2024102012381394000_62.5.2301726.14","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/S0140-6736(22)01601-4","article-title":"The evolving landscape of pulmonary arterial hypertension clinical trials","volume":"400","author":"Weatherald","year":"2022","journal-title":"Lancet"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01726-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T08:14:56Z","timestamp":1740384896000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01726-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,11,2]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1183\/13993003.01726-2023"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01726-2023","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}